Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


WHO’s New Regulatory Benchmarking Framework To Go Live This Year

Egyptian And Nigerian Agencies Reach ‘Maturity Level 3’

Executive Summary

A new list of national regulators that want to be seen as meeting the highest international regulatory standards has been drawn up by the WHO in a drive to foster regulatory convergence and harmonization.

You may also be interested in...

First Three Medicine Regulators Gain ‘WHO-Listed Authority’ Status

Coronavirus Notebook: Six African Countries To Produce mRNA Vaccines, CEPI Funds Indian Candidates

Alvea, a US biotech startup, says its first two DNA vaccine candidates are undergoing “rigorous” preclinical testing and could enter clinical trials as early as April this year.

Feedback Sought On WHO Proposal For Recognizing Well-Performing Regulatory Agencies

The World Health Organization is seeking comments on a policy document explaining how it plans to evaluate and list regulatory authorities that meet international standards.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts